New appointment at Diasome Pharmaceuticals
This article was originally published in Scrip
The US clinical-stage diabetes therapeutics company Diasome Pharmaceuticals has appointed David King chairman of the board. Mr King was a founder and CEO of BioRexis Pharmaceutical, which was acquired by Pfizer. He also served as the CEO of Principia Pharmaceutical, which was acquired by Human Genome Sciences, and as president of Delsys Pharmaceutical, which was acquired by Elan.